Eisai R&d Management Co., Ltd.

Eisai Company, Limited

Yoshiaki Ohashi

Yu Yoshida

Yoshihisa Kobayashi

Tamaki Hoshikawa

Nobuaki Sato

Ichiro Yoshida

Yoshihiko Norimine

Shinsuke Hirota

Shuichi Suzuki

Nobuhiro Sato

Koji Hagiwara

Satoshi Inoue

Toru Watanabe

Keigo Tanaka

Mitsuaki Miyamoto

Nobuhisa Watanabe

Hitoshi Harada

Naoki Yoneda

Kogyoku Shin

Tadashi Okabe

Makoto Kotake

Junichi Kamata

Yasutaka Takase

Norio Murai

Shuji Shirotori

Kunitoshi Takeda

Yoichi Kita

Ikuo Kushida

Hiromitsu Yokohama

Yoshinori Sakuma

Kenshi Yoshida

Manabu Shirato

Hidenori Seshimo

Daisuke Ito

Takashi Fukuyama

Yasuaki Kamada

Tomoyuki Shibuguchi

Takaaki Harada

Toshiki Kurokawa

Yosuke Kaburagi

Hironori Fukumoto

Futoshi Miyazaki

Hikaru Yoshimura

Daiya Shimokubo

Yasunobu Matsumoto

Yuji Onizawa

Salts of the compound represented by formula (I) or crystals thereof have a potential use as drug substances for pharmaceuticals. 

Salt of pentacyclic compound and crystal thereof

The present invention provides compounds represented by formulas (I) to (XVII) or pharmaceutically acceptable salts thereof: 

Pentacyclic heterocycles

The present invention provides compounds represented by formulas (1) to (VI) or pharmaceutically acceptable salts thereof: 

Pentacyclic compound

Compounds represented by formulae (I) to (XXII) or pharmaceutically acceptable salts thereof: 

Pyranodipyridine compound

A compound represented by formula (1) or a pharmaceutically acceptable salt thereof has an inhibitory effect in the fractalkine-CX3CR1 pathway: wherein R represents a Calkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, a Ccycloalkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, or a Ccycloalkenyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group A, X represents a Calkyl group, Y and Z are the same or different from each other and each represents a halogen atom or a Calkyl group unsubstituted or having 1 to 3 substituents selected from Substituent Group B, n represents 0 or 1, Substituent Group A consists of halogen atoms, and Substituent Group B consists of halogen atoms.

Pyrrolidin-3-ylacetic acid derivative

The present invention provides compounds which are useful as safe substitutes for the organotin reagent used in coupling reaction for the oxymethylation of aromatic rings, such as alkoxymethylation or hydroxymethylation, with a palladium catalyst and which can dispense with chromatographic purification with silica gel in the production and are suitable for mass production; and compounds applicable even to the oxymethylation of aromatic ring substrates which do not permit coupling reaction by conventional technique or have low reactivity.

Oxymethyl boron compounds

The present invention discloses compounds and compositions of formula (I): having inhibitory activity on activation of STAT6, wherein X represents quinoline, isoquinoline, quinazoline or imidazopyridine; Y represents phenyl, piperazine, pyridine, thiophene, thiazole, oxathiazole or oxathiadiazole; and variables Z, n, R, R, Rand Rare as defined in the claims.

Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof

Growing community of inventors

Tsukuba, Japan

Yoshiaki Ohashi